Neuroinflammation and central sensitization are key mechanisms in chronic and widespread pain. Chronic pain is maintained by central sensitization, a process involving synaptic plasticity and increased neuronal responsiveness in pain pathways. Neuroinflammation, characterized by glial cell activation (microglia and astrocytes) and release of pro-inflammatory cytokines and chemokines, drives chronic pain. Central cytokines and chemokines act as neuromodulators, inducing hyperalgesia and allodynia. Sustained cytokine levels in the CNS promote chronic widespread pain. Sex-dependent glial/immune signaling and new therapeutic approaches targeting neuroinflammation are discussed. Chronic pain affects one in three Americans and costs the US economy $635 billion annually. Acute pain is protective, while chronic pain is maladaptive and characterized by spontaneous and evoked pain. Pain perception is linked to inflammation, which involves the somatosensory, immune, neuronal, autonomic, and vascular systems. Nociceptors, responding to tissue injury, are activated by inflammatory mediators and modulate immune responses. Neurogenic inflammation, caused by neuropeptides and prostanoids, leads to plasma extravasation and edema. Neurogenic inflammation contributes to pain conditions like migraine and complex regional pain syndrome (CRPS). Neuroinflammation is associated with various painful insults, including trauma, surgery, and autoimmune diseases. It is linked to neurological and neuropsychiatric diseases like Alzheimer’s and Parkinson’s. Neuroinflammation is also involved in chronic pain conditions such as fibromyalgia and temporomandibular disorder. Neuroinflammation in the CNS and PNS is driven by factors like chemotherapy, anti-HIV treatment, and chronic opioid use. Glial activation is a primary feature of neuroinflammation and a driver of chronic pain. Microglia and astrocytes are activated after painful injuries, leading to increased expression of markers and morphological changes. Glial activation is associated with pain hypersensitivity and is regulated by various signaling pathways. Cytokines and chemokines, such as TNF-α, IL-1β, and CCL2, play critical roles in neuroinflammation and central sensitization. Glial activation in the brain is also involved in regulating neuroinflammation and pain sensitivity. Sex dimorphism in glial regulation of allodynia and hyperalgesia is evident, with differences in microglial responses between males and females. Central sensitization is a key mechanism in chronic pain, involving increased synaptic efficacy and neuronal hyperactivity. NMDA receptor activation is essential for central sensitization, and signaling pathways like MAPK and ERK are involved in its induction and maintenance. Central sensitization can occur independently of peripheral input and is influenced by changes in central nervous system neurons. Neuroinflammation drives central sensitization and widespread pain through glia-produced cytokines and chemokinesNeuroinflammation and central sensitization are key mechanisms in chronic and widespread pain. Chronic pain is maintained by central sensitization, a process involving synaptic plasticity and increased neuronal responsiveness in pain pathways. Neuroinflammation, characterized by glial cell activation (microglia and astrocytes) and release of pro-inflammatory cytokines and chemokines, drives chronic pain. Central cytokines and chemokines act as neuromodulators, inducing hyperalgesia and allodynia. Sustained cytokine levels in the CNS promote chronic widespread pain. Sex-dependent glial/immune signaling and new therapeutic approaches targeting neuroinflammation are discussed. Chronic pain affects one in three Americans and costs the US economy $635 billion annually. Acute pain is protective, while chronic pain is maladaptive and characterized by spontaneous and evoked pain. Pain perception is linked to inflammation, which involves the somatosensory, immune, neuronal, autonomic, and vascular systems. Nociceptors, responding to tissue injury, are activated by inflammatory mediators and modulate immune responses. Neurogenic inflammation, caused by neuropeptides and prostanoids, leads to plasma extravasation and edema. Neurogenic inflammation contributes to pain conditions like migraine and complex regional pain syndrome (CRPS). Neuroinflammation is associated with various painful insults, including trauma, surgery, and autoimmune diseases. It is linked to neurological and neuropsychiatric diseases like Alzheimer’s and Parkinson’s. Neuroinflammation is also involved in chronic pain conditions such as fibromyalgia and temporomandibular disorder. Neuroinflammation in the CNS and PNS is driven by factors like chemotherapy, anti-HIV treatment, and chronic opioid use. Glial activation is a primary feature of neuroinflammation and a driver of chronic pain. Microglia and astrocytes are activated after painful injuries, leading to increased expression of markers and morphological changes. Glial activation is associated with pain hypersensitivity and is regulated by various signaling pathways. Cytokines and chemokines, such as TNF-α, IL-1β, and CCL2, play critical roles in neuroinflammation and central sensitization. Glial activation in the brain is also involved in regulating neuroinflammation and pain sensitivity. Sex dimorphism in glial regulation of allodynia and hyperalgesia is evident, with differences in microglial responses between males and females. Central sensitization is a key mechanism in chronic pain, involving increased synaptic efficacy and neuronal hyperactivity. NMDA receptor activation is essential for central sensitization, and signaling pathways like MAPK and ERK are involved in its induction and maintenance. Central sensitization can occur independently of peripheral input and is influenced by changes in central nervous system neurons. Neuroinflammation drives central sensitization and widespread pain through glia-produced cytokines and chemokines